Image 15_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.jpeg by Chen Wang (88408)

“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”

Image 4_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.tif by Chen Wang (88408)

“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”

Image 11_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.jpeg by Chen Wang (88408)

“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”

Image 5_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.tif by Chen Wang (88408)

“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”

Image 9_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.jpeg by Chen Wang (88408)

“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”

Data Sheet 1_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.pdf by Chen Wang (88408)

“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”

Image 2_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.jpeg by Chen Wang (88408)

“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”

Image 13_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.jpeg by Chen Wang (88408)

“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”

Image 1_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.tif by Chen Wang (88408)

“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”

<b>Collapsin response mediator protein 2 modulates synaptic function by stabilizing the surface expression of phosphorylated AMPA receptor GluA2 subunits</b> by ren (21408623)

“…Upon phorbol myristate acetate (TPA) induced activation of protein kinase C (PKC), the surface expression of GluA2 decreased significantly, as phosphorylation of GluA2 at the S880 site is known to promote its internalization. …”

Image 14_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.jpeg by Chen Wang (88408)

“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”

Image 12_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.jpeg by Chen Wang (88408)

“…Functional studies demonstrated that RBM15 loss led to increased expression of fumarate hydratase (FH). This led to decreased levels of fumarate, a metabolite known to suppress anti-tumor immune responses. …”

Mean liver weight (g) (A), liver weight/body ratio (B), hepatic triglyceride (mg/g) (C) and hepatic steatosis quantification (% area) (D) upon completion of the treatment phase. by Elsie D. Oduor (22521785)

Loss of C1-FDX results in a reduction of the CI and CV activity. by Baoyin Chen (2635399)

(A) The distribution of mutations within the 3D structure of the TP53 protein. by Ashraf Attia Mahmoud (21262201)

The speed diagram. by Yifei Li (198040)

“…A combination of bench and simulation tests validated the test results, showing no significant differences and confirming the method’s viability for determining COR. …”

Factors of orthogonal experiment. by Yifei Li (198040)

“…A combination of bench and simulation tests validated the test results, showing no significant differences and confirming the method’s viability for determining COR. …”

Analysis of variance in orthogonal test. by Yifei Li (198040)

“…A combination of bench and simulation tests validated the test results, showing no significant differences and confirming the method’s viability for determining COR. …”

Analysis of variance in orthogonal test. by Yifei Li (198040)

“…A combination of bench and simulation tests validated the test results, showing no significant differences and confirming the method’s viability for determining COR. …”

Effect of collision variety on COR. by Yifei Li (198040)

“…A combination of bench and simulation tests validated the test results, showing no significant differences and confirming the method’s viability for determining COR. …”